Price
Target price
€11.90
€11.90
-
-
-
€17.84
04.12.25 / Frankfurt
WKN: A2AF74 / Symbol: HCM / Name: Chi-Med / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Hutchison China MediTech Ltd ADR Stock
Our community is currently high on Hutchison China MediTech Ltd ADR with 3 Buy predictions and 1 Sell predictions.
With a target price of 17 € there is a positive potential of 42.86% for Hutchison China MediTech Ltd ADR compared to the current price of 11.9 €.
Pros and Cons of Hutchison China MediTech Ltd ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hutchison China MediTech Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hutchison China MediTech Ltd ADR | - | 0.000% | -9.848% | -29.167% | -11.194% | -1.653% | -50.000% |
| China Resources Pharmaceutical Group Ltd | -0.950% | 0.000% | -3.670% | -17.323% | -22.222% | -33.121% | 23.821% |
| China Traditional Chinese Medicine Co Ltd | -0.820% | -1.613% | 0.000% | -9.630% | -10.294% | -46.018% | -38.071% |
| Repligen Corp. | -0.880% | -4.075% | 11.207% | 0.743% | 1.751% | -20.349% | -8.247% |
Comments
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $13.75 price target on the stock.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM) had its price target raised by analysts at Bank of America Corporation from $27.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HCM provided by MarketBeat
